Calypte Biomedical Corp.

At March 31, 2010, Calypte Biomedical Corporation had a working capital deficit of US$16.5 million, including US$11.6 million in principal and accrued interest under the 8% convertible notes and 7%…

Calypte Biomedical Corporation had working capital deficits of US$16.6 million and US$14.5 million, at December 31, 2009, and 2008, respectively.

For the year ended December 31, 2009, the Company suffered a…